GlassScriptPhysician profile
Steven Pribanich
NPI 1912918343
$683.16
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $43.16 · 2021: $91.34 · 2022: $54.22 · 2023: $170 · 2024: $23.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $193.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $176.43 | 2019-2023 | Farxiga |
| Convatec INC. | $136.19 | 2023 | |
| Glaxosmithkline, LLC. | $67.81 | 2019-2022 | |
| Novo Nordisk INC | $49.41 | 2019 | |
| Antares Pharma, INC. | $46.89 | 2019-2022 | |
| Abbvie INC. | $26.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $25.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.96 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.68 | 2024 | Caplyta |
| Abbott Laboratories | $20.64 | 2021 | |
| Dexcom, INC. | $19.41 | 2021 | |
| Halozyme INC | $18.06 | 2023 | |
| Amgen INC. | $13.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.33 | 2019 | |
| Amarin Pharma, INC. | $11.22 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pribanich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.